Asuragen Strengthens Repetitive Sequence and Short Structural Variant Intellectual Property Portfolio
AUSTIN, Texas — (BUSINESS WIRE) — Asuragen, Inc., a global molecular diagnostics company, announced today the award of a patent (EP 2,411,532 B1) from the European Patent Office for PCR methods that analyze the presence of an interrupter sequence in CGG-rich regions of the fragile X mental retardation (FMR1) gene. This latest patent further strengthens Asuragen’s intellectual property portfolio, which includes 36 issued or pending US and international patents related to the study of the FMR1 gene and other high homology sequences.
Highly repetitive regions of the genome pose significant hurdles to reliable genetic analysis. By driving innovation through reduced complexity, optimized workflow, and quality performance, Asuragen’s technologies provide researchers with the tools to investigate the most challenging and difficult-to-analyze targets in the genome.
“The innovations recognized in these patents are the foundation of Asuragen’s growing genetic product portfolio,” said Matt McManus, MD, PhD, President and CEO of Asuragen. “Our repeat sequence and high homology sequence technologies are uniquely suited to serve the emerging clinical testing needs for short structural variants in genetic disorders and cancer.”
Asuragen overcame a 20-year obstacle by reliably amplifying FMR1 gene regions, resulting in a market-leading, PCR-only approach to detect and characterize fragile X repeat expansions, including full mutations and their corresponding methylation states. The scientific value of this product portfolio is represented in more than 40 peer-reviewed publications since 2010.
Asuragen’s six patent families cover proprietary methods for both GC- and AT-rich amplification, the detection of interruptions in repeat sequences, the sizing of repeat regions, automated reconstructions of FMR1 genotypes, and methylation PCR of repeat sequences. Asuragen’s AmplideX genetic product portfolio includes PCR/CE FMR1*†, C9orf72* and TOMM40* RUO Kits.
*For Research Use Only. Not for use in diagnostic procedures. †CE-IVD for US export only.
Asuragen is a global diagnostic products company delivering solutions that build knowledge and understanding of complex clinical questions. Asuragen’s application of its deep scientific heritage and molecular expertise delivers diagnostic products in oncology and genetics that provide the best answers with optimal workflows – so time can be spent delivering actionable insights, rather than searching for them. With innovative approaches to kit development and a broad range of molecular chemistries, Asuragen produces assays that ensure reproducible results. From discovery and development to regulatory support to global commercialization, we also provide a tailored approach that efficiently delivers custom and companion diagnostic products for our partners. We believe people deserve better answers. For more information, visit www.asuragen.com.
SVP, Corporate Development and Chief Financial Officer